Literature DB >> 15245824

Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16.

Monika Jung, Chuanliang Xu, Jan Spethmann, Manfred Johannsen, Serdar Deger, Carsten Stephan, Stefan A Loening, Klaus Jung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15245824     DOI： 10.1016/j.eururo.2004.03.003

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  15 in total

1.  Label-free in vitro prostate cancer cell detection via photonic-crystal biosensor.

Authors:  Frank DeLuna; XiaoFei Ding; Ismael Sagredo; Gilbert Bustamante; Lu-Zhe Sun; Jing Yong Ye
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2018-02-20

Review 2.  Roles for long non-coding RNAs in physiology and disease.

Authors:  Maria-Theodora Melissari; Phillip Grote
Journal:  Pflugers Arch       Date:  2016-03-05       Impact factor: 3.657

Review 3.  Biomarkers for prostate cancer.

Authors:  Eric Schiffer
Journal:  World J Urol       Date:  2007-08-10       Impact factor: 4.226

Review 4.  PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.

Authors:  Zheng Yang; Lu Yu; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

5.  Cellular Refractive Index Comparison of Various Prostate Cancer and Noncancerous Cell Lines via Photonic-Crystal Biosensor.

Authors:  Frank DeLuna; Melissa Cadena; Bingzhi Wang; Lu-Zhe Sun; Jing Yong Ye
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2019-03-04

Review 6.  Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer.

Authors:  Yin-Jie Su; Jin Yu; Ya-Qin Huang; Jin Yang
Journal:  Int J Mol Sci       Date:  2015-06-11       Impact factor: 5.923

7.  PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience.

Authors:  Roberta Merola; Luigi Tomao; Anna Antenucci; Isabella Sperduti; Steno Sentinelli; Serena Masi; Chiara Mandoj; Giulia Orlandi; Rocco Papalia; Salvatore Guaglianone; Manuela Costantini; Giuseppe Cusumano; Giovanni Cigliana; Paolo Ascenzi; Michele Gallucci; Laura Conti
Journal:  J Exp Clin Cancer Res       Date:  2015-02-06

Review 8.  Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review.

Authors:  Michael A Liss; Robin J Leach; Martin G Sanda; Oliver J Semmes
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-22       Impact factor: 4.254

9.  TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.

Authors:  J F Knight; C J Shepherd; S Rizzo; D Brewer; S Jhavar; A R Dodson; C S Cooper; R Eeles; A Falconer; G Kovacs; M D Garrett; A R Norman; J Shipley; D L Hudson
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

10.  Markers for detection of prostate cancer.

Authors:  Raymond A Clarke; Horst J Schirra; James W Catto; Martin F Lavin; Robert A Gardiner
Journal:  Cancers (Basel)       Date:  2010-06-04       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.